BCR and diffuse large B-cell lymphoma: However, ibrutinib continues to hold promise as an effective strategy for BCR signal inhibition, at least in certain DLBCL subtypes: in a recent phase I/II clinical trial of relapsed or refractory DLBCL, ibrutinib achieved 37% complete or partial responses in ABC subtype but only 5% response in GCB DLBCL, underscoring the importance of BCR signaling in the pathogenesis of ABC type tumors [14].